Agios Pharmaceuticals (AGIO) Insider Trading & Ownership $34.54 -0.81 (-2.29%) (As of 11:09 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Agios Pharmaceuticals (NASDAQ:AGIO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.93%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$2.12 M Get AGIO Insider Trade Alerts Want to know when executives and insiders are buying or selling Agios Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AGIO Insider Buying and Selling by Quarter Ad Stansberry Research"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says it could be the worst U.S. financial crisis in 200 years. Before the next trading session begins, I highly recommend you review Dan's action plan to secure your gains, even if the market falls from here.Click here to see how Dan says you could profit from the American "Mega Bubble" of 2025. Agios Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/11/2024David ScaddenDirectorSell200$46.28$9,256.00 9/26/2024Cecilia JonesCFOSell2,542$49.03$124,634.26 8/8/2024Brian GoffCEOSell11,091$42.75$474,140.25 4/10/2024Jacqualyn A FouseDirectorSell7,791$27.55$214,642.05 3/5/2024Brian GoffCEOSell4,156$32.57$135,360.92 3/5/2024James William BurnsInsiderSell2,642$32.57$86,049.94 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 3/5/2024Kaye I Foster-CheekDirectorSell300$32.21$9,663.00 2/20/2024Theodore James Jr. WashburnInsiderSell504$26.63$13,421.52 2/14/2024Sarah GheuensInsiderSell642$25.14$16,139.88 1/24/2024Brian GoffCEOSell7,635$21.64$165,221.40 1/24/2024Cecilia JonesCFOSell1,886$21.64$40,813.04 1/24/2024Jacqualyn A FouseDirectorSell10,722$21.64$232,024.08 1/24/2024James William BurnsInsiderSell1,708$21.64$36,961.12 1/24/2024Josh GottheimerU.S. Congress Member (D-NJ)Buy$21.51$1,001 - $15,0001/9/2024Brian GoffCEOSell12,066$22.99$277,397.34 1/9/2024Jacqualyn A FouseDirectorSell8,391$22.99$192,909.09 1/9/2024James William BurnsInsiderSell1,163$22.99$26,737.37 1/5/2024Tsveta MilanovaInsiderSell2,902$22.32$64,772.64 (Data available from 1/1/2013 forward) AGIO Insider Trading Activity - Frequently Asked Questions Who is on Agios Pharmaceuticals's Insider Roster? The list of insiders at Agios Pharmaceuticals includes Brian Goff, Cecilia Jones, David P Schenkein, David Scadden, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek, Sarah Gheuens, Theodore James Jr. Washburn, and Tsveta Milanova. Learn more on insiders at AGIO. What percentage of Agios Pharmaceuticals stock is owned by insiders? 4.93% of Agios Pharmaceuticals stock is owned by insiders. Learn more on AGIO's insider holdings. Which Agios Pharmaceuticals insiders have been selling company stock? The following insiders have sold AGIO shares in the last 24 months: Brian Goff ($1,376,813.55), Cecilia Jones ($264,755.63), David P Schenkein ($3,002,694.55), David Scadden ($9,256.00), Jacqualyn A Fouse ($943,537.70), James William Burns ($366,219.55), Kaye I Foster-Cheek ($658,663.00), Sarah Gheuens ($16,139.88), Theodore James Jr. Washburn ($138,443.95), and Tsveta Milanova ($64,772.64). How much insider selling is happening at Agios Pharmaceuticals? Insiders have sold a total of 256,636 Agios Pharmaceuticals shares in the last 24 months for a total of $6,841,296.45 sold. Which members of congress are trading Agios Pharmaceuticals? Josh Gottheimer (D-NJ) has bought shares of Agios Pharmaceuticals in the last year totaling $8,000. Agios Pharmaceuticals Key ExecutivesMr. Brian M. Goff M.B.A. (Age 55)CEO & Director Compensation: $1.23MMs. Cecilia Jones (Age 49)Chief Financial Officer Compensation: $403.36k1 recent tradesMr. James William Burns (Age 46)Corporate Secretary & Chief Legal Officer Compensation: $660.33kDr. Sarah Gheuens M.D. (Age 44)Ph.D., Chief Medical Officer and Head of Research & Development Compensation: $769.2kDr. Lewis Clayton Cantley Ph.D. (Age 75)Co-Founder & Member of Scientific Advisory Board Compensation: $50kDr. Tak Wah Mak D.Sc. (Age 78)FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Craig B. Thompson M.D. (Age 71)Co-Founder & Chairman of Scientific Advisory Board Dr. Shin-San Su Ph.D. (Age 68)Co-Founder & Member of Scientific Advisory Board Mr. T. J. Washburn Jr. (Age 43)Principal Accounting Officer Dr. Clive Patience Ph.D. (Age 60)Chief Technical Operations Officer More Insider Trading Tools from MarketBeat Related Companies ITCI Insider Transactions ROIV Insider Transactions RVMD Insider Transactions LNTH Insider Transactions NUVL Insider Transactions BPMC Insider Transactions ELAN Insider Transactions CYTK Insider Transactions TGTX Insider Transactions VKTX Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:AGIO) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
